AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended)

A compound selected from the group consisting of all possible isomeric forms and their mixtures, a compound of the formula



I

either R_1 is hydrogen or methyl and R_2 is selected from the group consisting of

~~cyclohexyl substituted by an amine,~~ $-CH_2-CH_2NHCH_3$,



$-CH_2CHCH_3NH_2$,



-$CHCH_3CH_2NH_2$, -(CH2)aOH where a is an integer of 1 to 8, -$(CH_2)_b$ ~~B~~-C≡N where b is an integer of 1 to 8, -$CHCH_3C_6H_5$, -(CH_2)-$C(CH_3)_2NHCOCF_3$, and –$CHCH_3(CH_2)$dOH where d is an integer of 1 to 8,

~~or R_1 and R_2 together with the nitrogen to which they are attached form a ring of 3, 4 or 5 carbons optionally substituted by an amine~~

R_3 is selected from the group consisting of hydrogen, methyl and hydroxyl,

R_4 is hydrogen or hydroxyl,

R is selected from the group consisting of alkyl and cycloalkyl of up to 30 carbon atoms, optionally containing at least one heteroatom, at least one heterocycle and alkyl or cyclic acyl of up to 30 carbon atoms optionally containing at least one heteroatom, and at least one heterocycle,

T is selected from the group consisting of hydrogen, methyl, -CH_2CONH_2, ~~-CH_2=N~~ –CH_2-C≡N, and -$(CH_2)_2NH_2$,

Y is selected from the group consisting of hydrogen, hydroxyl, halogen and –OSO_3H or a salt thereof,

W is hydrogen or OH,

Z is hydrogen or methyl and its non-toxic, pharmaceutically acceptable acid addition salt.

Claim 2 (previously presented)

The compound of claim 1 in which T is hydrogen.

Claim 3 (previously presented)

The compound of claim 1 in which W is hydrogen.

Claim 4 (previously presented)

The compound of claim 1 in which Z is methyl.

Claim 5 (previously presented)

The compound of claim 1 in which Y is hydrogen.

Claim 6 (previously presented)

The compound of claim 1 in which R_3 is methyl.

Claim 7 (previously presented)

The compound of claim 1 in which R_4 is hydroxyl.

Claim 8 (previously presented)

The compound of claim 1 in which R is selected from the group consisting of





































Claim 9 (previously presented)

The compound of claim 8 in which R is



Claim 10 (previously presented)

The compound of claim 8 in which R is



Claim 11 (previously presented)

The compound of claim 1 in which R_1 is hydrogen.

Claim 12 (cancelled)

Claim 13 (previously presented)

The compound of claim 1 in which R_2 is selected from the group consisting of



$-CH_2-C(CH_2)_2-NH_2$, $-CH_2-CH(CH_3)-NH_2$, and $-CH(CH_3)-CH_2NH_2-$

Claim 14 (previously presented)

The compound of claim 1 in which R_2 is



Claim 15 (currently amended)

The compound of claim 1 <u>is</u> ~~selected from the group consisting of~~

- 1-[4-[[(1H-benzimidazol-2-yl)-methyl)-amino-N2-[[4"-(pentyloxy) [1,2':4', 1"
- terphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]5-L-serine-echinocandine B trifluoroacetate (isomer B), and
- ~~trans 1-[4-[(2-aminocyclo-hexyl)-amino]-N2-[[4"(pentyloxy)-[1,1':4', 1"-terphenyl]-4-yl-carbonyl]-L-ornithine]-4-[4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B-trifluoroacetate (isomer A)~~.

Claim 16 (cancelled)

Claims 17 and 18 (cancelled)

Claim 19 (previously presented)

An antifungal composition comprising an antifungally effective amount of a compound of claim 15 and an inert pharmaceutical carrier.

Claim 20 (previously presented)

A method of treating fungal infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antifungally effective amount of a compound of claim 15.